This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mouton, J. W.
Right arrow Articles by Craig, W. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mouton, J. W.
Right arrow Articles by Craig, W. A.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, October 1999, p. 2473-2478, Vol. 43, No. 10
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.

Use of Pharmacodynamic Indices To Predict Efficacy of Combination Therapy In Vivo

Johan W. Mouton,1,2,* Marc L. van Ogtrop,3,4 David Andes,4 and William A. Craig4

Erasmus University Rotterdam, Rotterdam,1 Canisius Wilhelmina Hospital, Nijmegen,2 and Leiden University Medical Centre, Leiden,3 The Netherlands, and University of Wisconsin, Madison, Wisconsin4

Received 21 December 1998/Returned for modification 15 May 1999/Accepted 30 July 1999

Although combination therapy with antimicrobial agents is often used, no available method explains or predicts the efficacies of these combinations satisfactorily. Since the efficacies of antimicrobial agents can be described by pharmacodynamic indices (PDIs), such as area under the concentration-time curve (AUC), peak level, and the time that the concentration is above the MIC (time>MIC), it was hypothesized that the same PDIs would be valid in explaining efficacy during combination therapy. Twenty-four-hour efficacy data (numbers of CFU) for Pseudomonas aeruginosa in a neutropenic mouse thigh model were determined for various combination regimens: ticarcillin-tobramycin (n = 41 different regimens), ceftazidime-netilmicin (n = 60), ciprofloxacin-ceftazidime (n = 59), netilmicin-ciprofloxacin (n = 38) and for each of these agents given singly. Multiple regression analysis was used to determine the importance of various PDIs (time>MIC, time>0.25× the MIC, time>4× the MIC, peak level, AUC, AUC/MIC, and their logarithmically transformed values) during monotherapy and combination therapy. The PDIs that best explained the efficacies of single-agent regimens were time>0.25× the MIC for beta-lactams and log AUC/MIC for ciprofloxacin and the aminoglycosides. For the combination regimens, regression analysis showed that efficacy could best be explained by the combination of the two PDIs that each best explained the response for the respective agents given singly. A regression model for the efficacy of combination therapy was developed by use of a linear combination of the regression models of the PDI with the highest R2 for each agent given singly. The model values for the single-agent therapies were then used in that equation, and the predicted values that were obtained were compared with the experimental values. The responses of the combination regimens could best be predicted by the sum of the responses of the single-agent regimens as functions of their respective PDIs (e.g., time>0.25× the MIC for ticarcillin and log AUC/MIC for tobramycin). The relationship between the predicted response and the observed response for the combination regimens may be useful for determination of the presence of synergism. We conclude that the PDIs for the individual drugs used in this study are class dependent and predictive of outcome not only when the drugs are given as single agents but also when they are given in combination. When given in combination, there appears to be a degree of synergism independent of the dosing regimen applied.

* Corresponding author. Mailing address: Department of Medical Microbiology, Canisius Wilhelmina Hospital, Weg door Jonkerbos 100, 6532 sz Nijmegen, The Netherlands. Phone: 31-(0)24-3657514. Fax: 31-(0)24 3657516. E-mail: Mouton{at}cwz.nl.

Antimicrobial Agents and Chemotherapy, October 1999, p. 2473-2478, Vol. 43, No. 10
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Grayo, S., Lott-Desroches, M.-C., Dussurget, O., Respaud, R., Fontanet, A., Join-Lambert, O., Singlas, E., Le Monnier, A. (2008). Rapid Eradication of Listeria monocytogenes by Moxifloxacin in a Murine Model of Central Nervous System Listeriosis. Antimicrob. Agents Chemother. 52: 3210-3215 [Abstract] [Full Text]  
  • Lode, H. (2007). Combination versus monotherapy for nosocomial pneumonia. ERR 16: 50-55 [Abstract] [Full Text]  
  • Rubino, C. M., Capparelli, E. V., Bradley, J. S., Blumer, J. L., Kearns, G. L., Reed, M., Jacobs, R. F., Cirincione, B., Grasela, D. M. (2007). Population Pharmacokinetic Model for Gatifloxacin in Pediatric Patients. Antimicrob. Agents Chemother. 51: 1246-1252 [Abstract] [Full Text]  
  • Domenech, A., Ribes, S., Cabellos, C., Taberner, F., Tubau, F., Dominguez, M. A., Montero, A., Linares, J., Ariza, J., Gudiol, F. (2005). Experimental study on the efficacy of combinations of glycopeptides and {beta}-lactams against Staphylococcus aureus with reduced susceptibility to glycopeptides. J Antimicrob Chemother 56: 709-716 [Abstract] [Full Text]  
  • Pankey, G. A., Ashcraft, D. S. (2005). In Vitro Synergy of Ciprofloxacin and Gatifloxacin against Ciprofloxacin-Resistant Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 49: 2959-2964 [Abstract] [Full Text]  
  • Navas, D., Caillon, J., Gras-Le Guen, C., Jacqueline, C., Kergueris, M.-F., Bugnon, D., Potel, G. (2004). Comparison of in vivo intrinsic activity of cefepime and imipenem in a Pseudomonas aeruginosa rabbit endocarditis model: effect of combination with tobramycin simulating human serum pharmacokinetics. J Antimicrob Chemother 54: 767-771 [Abstract] [Full Text]  
  • Barchiesi, F., Spreghini, E., Schimizzi, A. M., Maracci, M., Giannini, D., Carle, F., Scalise, G. (2004). Posaconazole and Amphotericin B Combination Therapy against Cryptococcus neoformans Infection. Antimicrob. Agents Chemother. 48: 3312-3316 [Abstract] [Full Text]  
  • Mouton, J. W., Schmitt-Hoffmann, A., Shapiro, S., Nashed, N., Punt, N. C. (2004). Use of Monte Carlo Simulations To Select Therapeutic Doses and Provisional Breakpoints of BAL9141. Antimicrob. Agents Chemother. 48: 1713-1718 [Abstract] [Full Text]  
  • Kadurugamuwa, J. L., Sin, L. V., Yu, J., Francis, K. P., Kimura, R., Purchio, T., Contag, P. R. (2003). Rapid Direct Method for Monitoring Antibiotics in a Mouse Model of Bacterial Biofilm Infection. Antimicrob. Agents Chemother. 47: 3130-3137 [Abstract] [Full Text]  
  • Ambrose, P. G., Bhavnani, S. M., Cirincione, B. B., Piedmonte, M., Grasela, T. H. (2003). Gatifloxacin and the elderly: pharmacokinetic-pharmacodynamic rationale for a potential age-related dose reduction. J Antimicrob Chemother 52: 435-440 [Abstract] [Full Text]  
  • Rex, J. H., Pfaller, M. A., Walsh, T. J., Chaturvedi, V., Espinel-Ingroff, A., Ghannoum, M. A., Gosey, L. L., Odds, F. C., Rinaldi, M. G., Sheehan, D. J., Warnock, D. W. (2001). Antifungal Susceptibility Testing: Practical Aspects and Current Challenges. Clin. Microbiol. Rev. 14: 643-658 [Abstract] [Full Text]  
  • Schiffelers, R. M., Storm, G., ten Kate, M. T., Stearne-Cullen, L. E. T., den Hollander, J. G., Verbrugh, H. A., Bakker-Woudenberg, I. A. J. M. (2001). In Vivo Synergistic Interaction of Liposome-Coencapsulated Gentamicin and Ceftazidime. J. Pharmacol. Exp. Ther. 298: 369-375 [Abstract] [Full Text]  
  • Robaux, M.-A., Dube, L., Caillon, J., Bugnon, D., Kergueris, M.-F., Navas, D., Le Conte, P., Baron, D., Potel, G. (2001). In vivo efficacy of continuous infusion versus intermittent dosing of ceftazidime alone or in combination with amikacin relative to human kinetic profiles in a Pseudomonas aeruginosa rabbit endocarditis model. J Antimicrob Chemother 47: 617-622 [Abstract] [Full Text]  
  • Andes, D., van Ogtrop, M. (2000). In Vivo Characterization of the Pharmacodynamics of Flucytosine in a Neutropenic Murine Disseminated Candidiasis Model. Antimicrob. Agents Chemother. 44: 938-942 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»